pioglitazone has been researched along with Cognitive Decline in 15 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study, it was examined whether treatment with PPAR‑γ agonist pioglitazone (PIO) is beneficial in counteracting SEV‑induced neuroinflammation and cognitive decline in a rat model of CIH." | 7.91 | Pioglitazone prevents sevoflurane‑induced neuroinflammation and cognitive decline in a rat model of chronic intermittent hypoxia by upregulating hippocampal PPAR‑γ. ( Dong, P; Fei, J; Li, D; Li, L; Li, N; Lin, Q; Lu, L; Yang, B; Zhang, X, 2019) |
| "Pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, is known to have anti-inflammatory and anti-oxidant effects on the brain, and its clinical potential in the treatment of cognitive impairment in diseases such as Alzheimer's disease (AD) and Parkinson disease (PD) is currently being explored." | 5.22 | Protective Effects of Pioglitazone on Cognitive Impairment and the Underlying Mechanisms: A Review of Literature. ( Aldubayan, M; Alhowail, A; Alsaud, M; Alsikhan, R; Rabbani, SI, 2022) |
| "Accumulating evidence indicates that elevated levels of methionine are associated with cognitive decline, including loss of memory." | 4.12 | The Protective Effects of Pioglitazone Against Cognitive Impairment Caused by L-methionine Administration in a Rat Model. ( Al-Azzam, SI; Alfaqih, M; Alrabadi, N; Alzoubi, KH; Khabour, OF; Mhaidat, NM; Tashtoush, M, 2022) |
| " In the present study, it was examined whether treatment with PPAR‑γ agonist pioglitazone (PIO) is beneficial in counteracting SEV‑induced neuroinflammation and cognitive decline in a rat model of CIH." | 3.91 | Pioglitazone prevents sevoflurane‑induced neuroinflammation and cognitive decline in a rat model of chronic intermittent hypoxia by upregulating hippocampal PPAR‑γ. ( Dong, P; Fei, J; Li, D; Li, L; Li, N; Lin, Q; Lu, L; Yang, B; Zhang, X, 2019) |
| "The onset of mild cognitive impairment (MCI) is an essential outcome in Alzheimer's disease (AD) prevention trials and a compelling milestone for clinically meaningful change." | 3.11 | Adjudicating Mild Cognitive Impairment Due to Alzheimer's Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial. ( Alexander, R; Bennett, DA; Burns, DK; Chiang, C; Culp, M; Farlow, MR; Haneline, S; Maresca, S; O'Neil, J; Peskind, ER; Raskind, MA; Sano, M; Saunders, AM; Schneider, LS; Stern, Y; Walter, R; Welsh-Bohmer, KA, 2022) |
| " There were no other notable differences in adverse events between groups." | 3.01 | Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. ( Alexander, RC; Burke, JR; Burns, DK; Chiang, C; Culp, M; Evans, RM; Haneline, S; Harrigan, P; Lutz, MW; O'Neil, J; Plassman, BL; Ratti, E; Saunders, AM; Schneider, LS; Schwarz, AJ; Welsh-Bohmer, KA; Wu, J; Yaffe, K, 2021) |
| "Rosiglitazone was not efficacious, even for apolipoprotein E (APOE) ε4 non-carriers (MD -0." | 2.52 | Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer's disease and amnestic mild cognitive impairment: a systematic review and meta-analysis. ( Jia, JP; Liu, J; Wang, LN, 2015) |
| "Treatment with fenofibrate, pioglitazone and their combination resulted in a significant improvement in the behavioural and neurochemical changes induced by βA injection." | 1.56 | Neuroprotective effect of PPAR alpha and gamma agonists in a mouse model of amyloidogenesis through modulation of the Wnt/beta catenin pathway via targeting alpha- and beta-secretases. ( Assaf, N; El Sayed, NS; El-Shamarka, ME; Khadrawy, YA; Salem, NA, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 9 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alhowail, A | 1 |
| Alsikhan, R | 1 |
| Alsaud, M | 1 |
| Aldubayan, M | 1 |
| Rabbani, SI | 1 |
| Schneider, LS | 2 |
| Bennett, DA | 1 |
| Farlow, MR | 1 |
| Peskind, ER | 1 |
| Raskind, MA | 1 |
| Sano, M | 1 |
| Stern, Y | 1 |
| Haneline, S | 2 |
| Welsh-Bohmer, KA | 2 |
| O'Neil, J | 2 |
| Walter, R | 1 |
| Maresca, S | 1 |
| Culp, M | 2 |
| Alexander, R | 1 |
| Saunders, AM | 3 |
| Burns, DK | 3 |
| Chiang, C | 2 |
| Alhowail, AH | 1 |
| Assaf, N | 1 |
| El-Shamarka, ME | 1 |
| Salem, NA | 1 |
| Khadrawy, YA | 1 |
| El Sayed, NS | 2 |
| Han, Y | 1 |
| Wang, J | 1 |
| Zhao, Q | 1 |
| Xie, X | 1 |
| Song, R | 1 |
| Xiao, Y | 1 |
| Kang, X | 1 |
| Zhang, L | 1 |
| Zhang, Y | 1 |
| Peng, C | 1 |
| You, Z | 1 |
| Qin, X | 1 |
| Wang, W | 1 |
| Wu, H | 1 |
| Liu, D | 1 |
| Wang, R | 1 |
| Xu, J | 1 |
| Jiang, H | 1 |
| Pan, F | 1 |
| Sánchez-Valle, R | 1 |
| Alexander, RC | 1 |
| Evans, RM | 1 |
| Harrigan, P | 1 |
| Plassman, BL | 1 |
| Burke, JR | 1 |
| Wu, J | 1 |
| Lutz, MW | 2 |
| Schwarz, AJ | 1 |
| Yaffe, K | 1 |
| Ratti, E | 1 |
| Alzoubi, KH | 1 |
| Khabour, OF | 1 |
| Alfaqih, M | 1 |
| Tashtoush, M | 1 |
| Al-Azzam, SI | 1 |
| Mhaidat, NM | 1 |
| Alrabadi, N | 1 |
| Ekladious, ST | 1 |
| Aghaei, I | 1 |
| Hajali, V | 1 |
| Haghani, M | 1 |
| Vaziri, Z | 1 |
| Moosazadeh, M | 1 |
| Shabani, M | 1 |
| Zhang, X | 1 |
| Li, N | 1 |
| Lu, L | 1 |
| Lin, Q | 1 |
| Li, L | 1 |
| Dong, P | 1 |
| Yang, B | 1 |
| Li, D | 1 |
| Fei, J | 1 |
| Roses, AD | 1 |
| Zhang, N | 1 |
| Hariri, AR | 1 |
| Asin, KE | 1 |
| Crenshaw, DG | 1 |
| Budur, K | 1 |
| Brannan, SK | 1 |
| Liu, J | 1 |
| Wang, LN | 1 |
| Jia, JP | 1 |
| Zhang, Z | 1 |
| Yuan, H | 1 |
| Zhao, H | 1 |
| Qi, B | 1 |
| Li, F | 1 |
| An, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Effica[NCT01931566] | Phase 3 | 3,494 participants (Actual) | Interventional | 2013-08-01 | Terminated (stopped due to Lack of efficacy of the drug; no safety concern) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Composite scores derived from the test battery. Domains of Episodic Memory [California Verbal Learning Test-2nd Edition (CVLT-II), Brief Visuospatial Memory Test-Revised (BVMT-R)]; Executive Function [Trail Making Test (TMT) (Part B), Wechsler Adult Intelligence Scale (WAIS)-III Digit Span Test-backwards span]; Language [Multilingual Naming Test (MiNT), Semantic Fluency (animals), Lexical/phonemic fluency (F, A, and S in English; D, S, and F in German)]; and Attention [WAIS-III Digit Span Test-forward span, TMT (Part A)] used for composite score. 12 measures were derived from 8 neuropsychological tests. CVLT-II test involved 2 primary measures (short, long delay recall); BVMT-R had 2 measures (copy and recall); Digit Span and Trail both had 2 measures (forward and backward span and Parts A and B). There was 1 total score for each test: CDT, MINT, semantic and lexical fluency. Total score ranged from -1.222 to 1.707 at baseline, a higher composite score indicated better cognition. (NCT01931566)
Timeframe: Baseline and Month 48
| Intervention | score on a scale (Mean) |
|---|---|
| High Risk Placebo | 0.1841 |
| High Risk Pioglitazone | 0.1687 |
The ADCS ADL-PI is a functional measure that was specifically designed for standardized administration over long duration clinical studies to prevent AD. The ADCS ADL-PI is a 20-item instrument that included 15 ADL questions, which were scored as 1 (with a lot of difficulty), 2 (with some difficulty), or 3 (as well as usually, with no difficulty), plus 5 vision, hearing, and mobility questions, which were scored from 0 (no) to 1 (yes). ADL Total ranged from 0 to 45, and lower scores indicated greater disability. (NCT01931566)
Timeframe: Baseline and Month 48
| Intervention | score on a scale (Mean) |
|---|---|
| High Risk Placebo | 0.1 |
| High Risk Pioglitazone | 0.3 |
The event definition for MCI-AD was the time in days from the randomization date to the date of the first of two consecutive scheduled visits at which a participant was assessed with a diagnosis of MCI due to AD confirmed by adjudication committee. Here, the time to event was reported as the restricted mean survival time. The restricted mean survival time was defined as the area under the curve of the survival function up to the largest event time. (NCT01931566)
Timeframe: Baseline to the end of study (approximately up to 5 years)
| Intervention | days (Mean) |
|---|---|
| High Risk Placebo | 1238.67 |
| High Risk Pioglitazone | 1261.24 |
The event definition for MCI-AD was the time in days from the randomization date to the date of the first of two consecutive scheduled visits at which a participant was assessed with a diagnosis of MCI due to AD confirmed by adjudication committee. Here, the time to event was reported as the restricted mean survival time. The restricted mean survival time was defined as the area under the curve of the survival function up to the largest event time. (NCT01931566)
Timeframe: Baseline to the end of study (approximately up to 5 years)
| Intervention | days (Mean) |
|---|---|
| Low Risk Placebo | 905.44 |
| High Risk Placebo | 1238.67 |
3 reviews available for pioglitazone and Cognitive Decline
| Article | Year |
|---|---|
Protective Effects of Pioglitazone on Cognitive Impairment and the Underlying Mechanisms: A Review of Literature.
Topics: Alzheimer Disease; Antioxidants; Cognitive Dysfunction; Humans; Hypoglycemic Agents; Parkinson Disea | 2022 |
New applications of disease genetics and pharmacogenetics to drug development.
Topics: Aged; Aged, 80 and over; Algorithms; Alzheimer Disease; Animals; Brain; Clinical Trials, Phase III a | 2014 |
Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer's disease and amnestic mild cognitive impairment: a systematic review and meta-analysis.
Topics: Alzheimer Disease; Cognitive Dysfunction; Humans; Hypoglycemic Agents; Pioglitazone; PPAR gamma; Ran | 2015 |
2 trials available for pioglitazone and Cognitive Decline
| Article | Year |
|---|---|
Adjudicating Mild Cognitive Impairment Due to Alzheimer's Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial.
Topics: Alzheimer Disease; Cognitive Dysfunction; Humans; Pioglitazone; Reproducibility of Results; Research | 2022 |
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Biomarkers, Pharmacological; Cognitive Dysfunction; Doub | 2021 |
10 other studies available for pioglitazone and Cognitive Decline
| Article | Year |
|---|---|
Pioglitazone ameliorates DOX-induced cognitive impairment by mitigating inflammation, oxidative stress, and apoptosis of hippocampal neurons in rats.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Chemotherapy-Related Cognitive Impairment | 2024 |
Neuroprotective effect of PPAR alpha and gamma agonists in a mouse model of amyloidogenesis through modulation of the Wnt/beta catenin pathway via targeting alpha- and beta-secretases.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Cognitive D | 2020 |
Pioglitazone alleviates maternal sleep deprivation-induced cognitive deficits in male rat offspring by enhancing microglia-mediated neurogenesis.
Topics: Animals; Cognition; Cognitive Dysfunction; Female; Hippocampus; Male; Microglia; Neurogenesis; Piogl | 2020 |
PPARγ-mediated microglial activation phenotype is involved in depressive-like behaviors and neuroinflammation in stressed C57BL/6J and ob/ob mice.
Topics: Animals; Behavior, Animal; Cognitive Dysfunction; Cytokines; Depression; Disease Models, Animal; Hip | 2020 |
Pioglitazone for prevention of cognitive impairment: results and lessons.
Topics: Cognitive Dysfunction; Humans; Hypoglycemic Agents; Pioglitazone | 2021 |
The Protective Effects of Pioglitazone Against Cognitive Impairment Caused by L-methionine Administration in a Rat Model.
Topics: Animals; Antioxidants; Cognitive Dysfunction; Hippocampus; Hypoglycemic Agents; Male; Maze Learning; | 2022 |
Effect of pioglitazone and simvastatin in lipopolysaccharide-induced amyloidogenesis and cognitive impairment in mice: possible role of glutamatergic pathway and oxidative stress.
Topics: Amyloid beta-Peptides; Animals; Cerebral Cortex; Cognitive Dysfunction; Disease Models, Animal; Dose | 2019 |
Peroxisome proliferator-activated receptor-γ activation attenuates harmaline-induced cognitive impairments in rats.
Topics: Animals; Behavior, Animal; Cognitive Dysfunction; Essential Tremor; Harmaline; Male; Maze Learning; | 2019 |
Pioglitazone prevents sevoflurane‑induced neuroinflammation and cognitive decline in a rat model of chronic intermittent hypoxia by upregulating hippocampal PPAR‑γ.
Topics: Animals; Chronic Disease; Cognitive Dysfunction; Disease Models, Animal; Hippocampus; Hypoglycemic A | 2019 |
PPARγ activation ameliorates postoperative cognitive decline probably through suppressing hippocampal neuroinflammation in aged mice.
Topics: Aging; Anilides; Animals; Brain-Derived Neurotrophic Factor; Cells, Cultured; Cognitive Dysfunction; | 2017 |